Form 4: 5AM Ventures Entities Execute Planned Sales of Entrada Therapeutics Stock

Entities affiliated with 5AM Ventures, a significant shareholder and director of Entrada Therapeutics, Inc., have reported the sale of common stock totaling 125,000 shares through pre-arranged Rule 10b5-1 trading plans.

Summary

• 5AM Ventures V, L.P. and 5AM Opportunities I, L.P., both 10% owners and affiliated with directors of Entrada Therapeutics, Inc. (TRDA), reported sales of common stock.
• On June 27, 2025, 5AM Ventures V, L.P. sold 55,735 shares directly at $6.91 per share, and 5AM Opportunities I, L.P. sold 19,265 shares indirectly at $6.91 per share.
• On June 30, 2025, 5AM Ventures V, L.P. sold 18,578 shares directly at $6.8127 per share, and 5AM Opportunities I, L.P. sold 6,422 shares indirectly at $6.8127 per share.
• On July 1, 2025, 5AM Ventures V, L.P. sold 18,578 shares directly at $7.1226 per share, and 5AM Opportunities I, L.P. sold 6,422 shares indirectly at $7.1226 per share.
• Following these transactions, 5AM Ventures V, L.P. directly holds 3,183,131 shares, and 5AM Opportunities I, L.P. indirectly holds 1,100,248 shares.
• The total number of shares sold across these dates amounts to 125,000 shares.
• All reported transactions were executed pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While insider sales can be concerning, the explicit mention of a Rule 10b5-1 plan indicates these are pre-scheduled divestments, which are less indicative of a negative outlook on the company's future performance and are a normal part of a venture fund's lifecycle.

Positives

• The sales were conducted under a Rule 10b5-1 plan, indicating they were pre-scheduled and not based on new, non-public information, which can mitigate negative market perception.

Negatives

• Significant sales by a 10% owner and director-affiliated entities could be perceived by some investors as a reduction in confidence, despite being pre-planned.

Risks

• Market perception risk due to insider sales, even if pre-planned, which could lead to short-term share price volatility.
• Potential for reduced institutional investor confidence if the sales are misinterpreted as a lack of belief in the company's future prospects.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• 5AM Partners V, LLC is the sole general partner of 5AM Ventures V, L.P., and Dr. Kush Parmar, Andrew J. Schwab, and Dr. Scott M. Rocklage are managing members of 5AM Partners, potentially having shared voting and investment power.
• 5AM Opportunities I (GP), LLC is the sole general partner of 5AM Opportunities I, L.P., and Andrew J. Schwab and Dr. Kush Parmar are managing members of Opportunities GP, potentially having shared voting and investment power.
• Each of the reporting entities and individuals (5AM Partners, Mr. Schwab, Dr. Rocklage, Opportunities GP) disclaims beneficial ownership of the shares of Common Stock held by 5AM Ventures V, L.P. and 5AM Opportunities I, L.P., except to the extent of its or his pecuniary interest therein.
• Dr. Parmar is a director of the Issuer and files separate Section 16 reports.

Industry Context

This filing reflects a common practice where venture capital firms, after a company's IPO, may gradually divest their holdings over time, often through pre-arranged trading plans, as part of their fund's lifecycle and investment strategy. Such sales are typical for early-stage investors transitioning out of their positions.

Related Party Transactions

• Sales of common stock by 5AM Ventures V, L.P. and 5AM Opportunities I, L.P., which are 10% owners and affiliated with directors of Entrada Therapeutics, Inc.

Stakeholder Impact

• Shareholders may react to the news of insider sales, potentially leading to short-term fluctuations in stock price, although the 10b5-1 plan mitigates the negative implications.

Key Dates

Recommendation

Keywords

Entrada Therapeutics, TRDA, Form 4, Insider Trading, Stock Sale, Beneficial Ownership, 5AM Ventures, Rule 10b5-1, Director Sales, 10% Owner